In vivo analysis of HIV replication and persistence in the myeloid compartment

Similar documents
Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin

BLT mice in HIV prophylaxis

Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington

Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice

Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4 + CD8 + thymocytes

Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)

HIV replication and latency in a humanized NSG mouse model during suppressive oral

HIV associated CNS disease in the era of HAART

Transfer protocol of human HSC into NOG mice

Joint Department of Biomedical Engineering

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

HIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.

HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model

Supporting Information

Targeting latent HIV infection: on the road towards an HIV Cure

Nature Immunology: doi: /ni.3412

Natural history of HIV Infection

Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation

Continuing Education for Pharmacy Technicians

SUPPLEMENTARY INFORMATION

HIV replication and selection of resistance: basic principles

HIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis

MedChem 401~ Retroviridae. Retroviridae

Nature Medicine: doi: /nm.4411

HIV/AIDS in Practice. An Expert Commentary with Myron Cohen, MD. A Clinical Context Report

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

HIV Treatment Guidelines

AIDS free generation. Bob Colebunders Institute of Tropical Medicine

Management of patients with antiretroviral treatment failure: guidelines comparison

Animal Models to Understand Immunity

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

Stem cells: units of development and regeneration. Fernando D. Camargo Ph.D. Whitehead Fellow Whitehead Institute for Biomedical Research.

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

pplementary Figur Supplementary Figure 1. a.

T cell manipulation of the graft: Yes

HIV & AIDS: Overview

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

What's new in the WHO ART guidelines How did markets react?

CHAPTER - IV OBJECTIVES OF THE STUDY

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

Guanhan Li. Section of Infections of the Nervous System National Institutes of Health, Bethesda, MD

HIV 101: Fundamentals of HIV Infection

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

Recombinant Protein Expression Retroviral system

HIV life cycle revisited: What s new in basic science? Theresa Rossouw

MID-TERM EXAMINATION

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

PEP, PREP, HPTN052 and MLN2238

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1

Central Nervous System Penetration of ARVs: Does it Matter?

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection

The Struggle with Infectious Disease. Lecture 6

Advances in HIV science and treatment. Report on the global AIDS epidemic,

February 14, 2003 Report on preclinical studies in gc-ko mice Fabio Candotti

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

The continuous spread of the AIDS epidemic, with over 2.7 million new human immunodeficiency virus (HIV) infections

Nature Medicine: doi: /nm.4322

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015

Professor Jonathan Weber

Human Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS

I. Bacteria II. Viruses including HIV. Domain Bacteria Characteristics. 5. Cell wall present in many species. 6. Reproduction by binary fission

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

Viral Genetics. BIT 220 Chapter 16

DISCOVERING ATCC IMMUNOLOGICAL CELLS - MODEL SYSTEMS TO STUDY THE IMMUNE AND CARDIOVASCULAR SYSTEMS

Central Nervous System Compartmentalization of HIV-1 Subtype C Variants Early and Late in Infection in Young Children

Case # 1. Case #1 (cont d)

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

227 28, 2010 MIDTERM EXAMINATION KEY

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

A phase I pilot study of safety and feasibility of stem cell therapy for AIDS lymphoma using stem cells treated with a lentivirus vector encoding

Immune System. Biol 105 Lecture 16 Chapter 13

Tools to Monitor HIV Infection in 2013 and Beyond.

Study Guide 23, 24 & 47

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir

Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results

Hematopoiesis. - Process of generation of mature blood cells. - Daily turnover of blood cells (70 kg human)

1. Overview of Adaptive Immunity

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

Principles of Antiretroviral Therapy

Body & Soul. Research update, 25 October 2016

CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies

DNA Genotyping in HIV Infection

Decay characteristics of HIV-1- infected compartments during combination therapy

Comprehensive evaluation of human immune system reconstitution in NSG. and NSG -SGM3 mouse models toward the development of a novel ONCO-HU

PART II! IMMUNE SENESCENCE!


cure research HIV & AIDS

HIV INFECTION: An Overview

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC

SUPPLEMENTARY INFORMATION

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

Transcription:

In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnulo and J. Victor Garcia Division of Infections Diseases UNC Center for AIDS Research University of North Carolina, at Chapel Hill

BLT Mouse Dendritic Cell CD8+ CD4+ http://cnx.org/

Macrophages/Microglia and HIV HIV-1 has evolved the ability to infect nondividing macrophages. HIV-1 infection and replication in microglia/ macrophages differs from that in CD4 + T lymphocytes. Specific cellular factors are required for HIV-1 transcription in macrophages. Monocytes/macrophages may serve to transmit HIV-1 to the central nervous system. Verani et al Mol. Imm. 2005

MoM: Myeloid-(only) Mouse model Created by transplantation of human CD34 + stem cells into pre-conditioned (irradiated) adult NOD/SCID mice. Human cells differentiate into B and myeloid lineages. However, these mice do not support human T cell production. Therefore the only targets for HIV infection are myeloid cells.

Experimental Design: Making MoMs CD34 + Cells

Systemic human reconstitution in MoM 44% 47% 6.1% 28% 36% 35% 87% 62% <1% <1% <1% <1%

Reconstitution of MoM brain with human myeloid cells

Are MoM susceptible to HIV-1 infection?

Experimental Design Viruses evaluated via intravenous injection Typical dose contained 360,000 TCIU high dose contained 720,000 TCIU of virus MoM injected with: CH040, CH040 4013env, JR-CSF, BaL, CH058, RHPA, HIV-2 (7321A), ADA or THRO CH040 4013env contains a macrophage-tropic envelope isolated from a patient

Viruses evaluated in MoM, BLT, & TOM as demonstrated by plasma VL (& tissue vdna) JR- CSF CH040 CH040-4013 env ADA BaL CH058 RHPA THRO HIV-2 (7321A) MoM 0/3 0/1 high 14/14 16/16 1/3 1/1 high 0/4 0/1 high 0/3 0/3 0/3 0/2 BLT All All 6/6 1/1 1/1 1/1 All All 4/4 TOM All 4/4 4/4 nd nd nd nd nd nd MoM=myeloid only humanized mouse TOM=T cell only humanized mice BLT=bone marrow, liver, thymus humanized mouse nd= not done

Sustained replication of virus in MoM CH040 (n=9) BLT TOM

Sustained replication of virus in MoM CH040 4013env (n=11) BLT TOM

Sustained replication of virus in MoM ADA (n=2) BL T

Lack of detectable levels of vdna in the peripheral blood cells from MoM

Systemic presence of HIV in MoMs (tissue vdna)

Systemic presence of HIV in MoMs (tissue vrna)

HIV infected cells are present in MoM brain hcd45 hcd68 HIV p24 Dr. Angela Wahl

Rescue of replication competent HIV from tissues obtained from infected MoM Cells were plated and allowed to adhere overnight Media was aspirated and 1 million CD4 + T cells (from healthy donor) were added to the culture HIV-RNA levels were measured in the supernatant after 10 days Virus Weeks Infected ART? Liver Lung Spleen BM ADA 6 N + + + + CH040 4 N + + + + CH040-4013 CH040-4013 5 N + + - + 5 N + + + +

HIV infection of MoMs MoM are systemically reconstituted with human myeloid and B cells (absence of T cells) MoM can systemically replicate HIV-1 over time Only certain viruses (CH040, CH040-4013, and ADA) Replication competent virus can be isolated from all infected MoM tissues

ART regimen Raltegravir integrase inhibitor Tenofovir NRTI Emtricitabine NRTI Mice administered treatment daily i.p.

ART effectively suppressed VL in CH040 infected MoMs

ART effectively suppressed VL in CH040 4013env infected MoMs

Viral load is effectively suppressed using ART in HIV infected MoM

Differences in suppression kinetics between MoMs, ToMs and BLTs Hu Type MoM BLT ToM MoM BLT Virus CH040-4013 env CH040 Weeks to undetectable plasma viral load 1-2 weeks 3-6 weeks 2-7 weeks 1-3 weeks 3-7 weeks

Summary MoM are systemically reconstituted with human myeloid cells. MoM infection with HIV results in sustained levels of viral RNA in PB and tissues in the complete absence of T cells demonstrating the direct contribution of myeloid cells to HIV replication in vivo. HIV replication in MoM is efficiently suppressed by ART. In MoM myeloid cells repopulate the brain. Myeloid cell in the brains of MoM are susceptible to productive HIV infection.

Jenna Honeycutt Angela Wahl Perry Tsai Rae Ann Spagnuolo Carolina Baker Patricia Sheridan Glenn Matsushima George Shaw Ron Swanstrom David Margolis Acknowledgements

Questions?